
GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research is well-positioned for success with its strong focus on developing innovative mebufotenin therapies targeting the critical unmet need of TRD patients. With the recent FDA clearance for CMC and device, GH is on track for a late-2026 pivotal start for its Phase III trial, which has already been designed to closely match the robust efficacy demonstrated in their Phase IIb dataset. Additionally, the current positive landscape in the psychedelics space should provide additional tailwinds for GH Research's success.
Bears say
GH Research is facing significant competition in the development of mebufotenin therapies, specifically their lead product candidate GH001 for the treatment of treatment-resistant depression (TRD). In addition, challenges with clinical trials and the potential for slower than expected adoption in the market due to a different mode of administration could impact the company's commercial success. These factors, combined with limited financials and only one segment focused on research and development, suggest a negative outlook on GH Research's stock.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares